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CK2Centrins are calcium-binding proteins that can interact with several cellular targets (Sﬁ1, XPC, Sac3
and transducin b) through the same hydrophobic triad. However, two different orientations of the
centrin-binding motif have been observed: W1xxL4xxxL8 for XPC (xeroderma pigmentosum group C
protein) and the opposite orientation L8xxxL4xxW1 for Sﬁ1 (suppressor of fermentation-induced loss
of stress resistance protein 1), Sac3 and transducin b. Centrins are also phosphorylated by several
protein kinases, among which is CK2. The purpose of this study was to determine the binding mech-
anism of human centrins to three targets (transducin b, Sﬁ1 and XPC), and the effects of in vitro
phosphorylation by CK2 of centrins 1 and 2 with regard to this binding mechanism. We identiﬁed
the centrin-binding motif at the COOH extremity of transducin b. Human centrin 1 binds to trans-
ducin b only in the presence of calcium with a binding constant lower than the binding constant
observed for Sﬁ1 and for XPC. The afﬁnity constants of centrin 1 were 0.10 106 M1, 249 106 M1
and 52.5 106 M1 for Trd, R17-Sﬁ1 and P17-XPC respectively. CK2 phosphorylates human centrin 1
at residue T138 and human centrin 2 at residues T138 and S158. Consequently CK2 phosphorylation
abolished the binding of centrin 1 to transducin b and reduced the binding to Sﬁ1 and XPC. CK2
phosphorylation of centrin 2 at T138 and S158 abolished the binding to Sﬁ1 as assessed using a C-
HsCen2 T138D-S158D phosphomimetic form of centrin 2.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The EF-hand superfamily is primarily composed of calmodulin,
and centrins, which are small Ca2+-binding proteins. Centrins were
ﬁrst identiﬁed in the unicellular green algae, Tetraselmis striata [1]
and Chlamydomonas reinhardtii [2] and are conserved proteins.
However, although lower eukaryotes such as unicellular algae
and yeast, possess only one centrin, higher eukaryotes possess
several isoforms that are generated by either gene duplication orretrotransposition from messenger RNA. These isoforms can inte-
grate into the chromosome as demonstrated by murine Cen1 [3]
and Cen4; in some cases, isoforms have been reduced to pseudo-
genes, such as in humans [4,5]. Centrins are composed of two
relatively independent EF-hand domains with each domain
containing two EF-hand motifs that bind Ca2+. Although the two
Ca2+-binding sites located within the C-terminal domain are func-
tional, the Ca2+-binding sites in the N-terminal domain may not be
functional, depending on the organism.
Centrins are localized to the centrosomes [6] and spindle pole
bodies in Saccharomyces cerevisiae [7]. Centrin 2 is ubiquitously
expressed, but centrin 1 expression is restricted to ciliated cells,
such as retinal photoreceptor cells [8]. Currently at least ﬁve cen-
trin-targets are known: XPC (xeroderma pigmentosum group C
protein), which has 1 centrin-binding site and, is involved in
DNA repair [9]; Sﬁ1 (suppressor of fermentation-induced loss of
stress resistance protein 1), which is a helicoid protein, has 25 cen-
trin-binding motifs and is involved in centrosome duplication and
cellular division [10]; Sac3 which is involved in RNA transfer from
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spindle pole bodies [12]; and transducin which is a G-protein
involved in the phototransduction cascade [13,14]. In all cases,
centrin binds its targets through a hydrophobic triad W1xxL4xxxL8
that was originally identiﬁed in XPC. However, in other centrin tar-
gets, such Sac3 and Sﬁ1, the triad is in the reverse orientation
L8xxxL4xxW1.
Two crystal structures of integral human centrin 2 in complex
with a 17-residue peptide derived from the human XPC [15,16]
and one crystal structure of yeast centrin Cdc31 in complex with
two or three repeats of S. cerevisiae Sﬁ1 [17] have been solved by
X-ray crystallography. From these structures, the residues involved
in the interaction between centrin and its targets have been deter-
mined, and the F113 residue of human centrin was identiﬁed as the
critical residue necessary to bind its targets (XPC and Sﬁ1) through
several contacts, especially with the W1 residue of the centrin-
targets.
Solution structures of centrin in apo form [18] as well as in
complex with either XPC [19] or Sﬁ1 [20] have also been resolved
using NMR. Because the helix dipoles of XPC and Sﬁ1 are in oppos-
ing orientations, the consequences of helix dipole orientation were
analyzed after the superimposition of the two NMR structures of
human centrin 2 in complex with either XPC or with Sﬁ1. For both
structures, the W residue of the triad is similarly embedded in the
cavity where the centrin F113 residue is situated. However, for
Sﬁ1, this implies a rotation of the W residue, which is accompanied
by a slight translation of the movement along the peptide helix
axis toward centrin 2. Owing to this movement the E148 residue,
which contacts XPC, is pushed out and is no longer able to contact
Sﬁ1.
Transducin is another centrin target that has been analyzed at
the cellular level; however, no structural study of the trans-
ducin–centrin complex has yet been conducted. Two transducin
b isoforms are found in the retina: transducin b1 is expressed in
rods and transducin b3 is expressed in cones. Experiments using
immunoelectron microscopy have shown that centrin and trans-
ducin co-localize in the connecting cilium of rod photocells in
mice, and co-immunoprecipitation studies and centrifugation and
size-exclusion chromatography experiments have demonstrated
that transducin b and the heterotrimer transducin abc bind to cen-
trin 1 [13]. The four isoforms of murine centrin have different sub-
cellular localizations. Cen1, 2, and 3 are found in the connecting
cilium although both Cen2 and Cen3 are found in the basal body
whereas Cen4 is only located in the basal body [14,21].
The heterotrimeric G proteins (abc) transduce and amplify
external signals. When GDP is bound to Ga it leads to the associa-
tion of Gawith the two other subunits bc. Furthermore, G protein-
coupled signaling is regulated by two mechanisms. The ﬁrst is the
intrinsic GTPase activity of Gta, by which Gta GTP is inactivated
and reassociates with Gtbc. Second, phosducin binds Gtbc thereby
blocking its association: with Gta. Phosducin was ﬁrst found in ret-
ina extracts but has since been shown to be expressed in various
tissues [22,23]. The structure of phosducin in complex with trans-
ducin bc has been solved using X-ray crystallography [24,25]. The
binding of phosducin to transducin bc is regulated by the phos-
phorylation of the S73 residue of phosducin by PKA. Phosphory-
lated phosducin then releases transducin b which then
reassociates with transducin a [26].
In vertebrate photoreceptor cells, centrins are phosphorylated
by the casein kinase CK2 in a light-dependent manner; this allows
CK2 to co-localize with the centrins in the inner lumen of the con-
necting cilium. As a consequence of phosphorylation, the centrins
have reduced afﬁnities for transducin [27]. CK2 has been shown
to phosphorylate murine centrin at T138, which is increased dur-
ing the dark adaptation of photoreceptor cells and leads to the
reduced binding of centrin to transducin. After illumination, thedephosphorylation of centrins by the PP2C-a and b phosphatases
[28] results in increased binding to transducin. The transport of
these proteins between the outer and inner segments at the ciliary
junctions of photoreceptor cells is also light-dependent. This infor-
mation, in addition to the large Ca2+ variations in these cells, sug-
gests that Ca2+ may be involved in the transport of these proteins
during the phototransduction cascade.
Because the centrin-binding motifs on XPC and both Sﬁ1 and
transducin b have an opposing orientation, we investigated the
effect of this inversion on the binding reaction. We also analyzed
the effect of phosphorylation of centrin on its binding to targets
based on the binding-motif orientation. The thermodynamics of
the binding of human centrin 1 to transducin b was assessed using
microcalorimetry and compared to the binding of other centrin tar-
gets (XPC, Sﬁ1). We report here that centrin 1 binds transducin b
exclusively in the presence of Ca2+, but with a lower afﬁnity than
that of centrin for its other targets XPC and Sﬁ1. A detailed study
using transducin b variants allowed us to determine which resi-
dues were responsible for this lower binding afﬁnity. We also
report that the phosphorylation of centrin 1 by CK2 regulates its
binding to transducin b. Additionally, we observed that CK2 phos-
phorylates human centrin 2 at T138 and S158 and consequently
regulates centrin 2 binding to Sﬁ1 and XPC.
2. Results
2.1. CK2 phosphorylates centrin 1 on T138 and centrin 2 at T138 and
S158
Both human centrins 1 and 2 (C-terminal domain including
residues M93 to Y172) have been shown to be phosphorylated
by the protein kinase CK2 (catalytic a and regulatory b subunits
complex). Consequently, one phosphorylated form of centrin 1
was generated, but two phosphorylated forms of centrin 2 were
identiﬁed by HPLC chromatography (Fig. S1A). The chromatograms
show that the phosphorylated centrin 1 was the only protein
observed after 24 h. Diphosphorylated centrin 2 was the primary
form observed after 24 h. The determination of the phosphorylated
residues was assessed using MALDI-TOF mass spectrometry of
trypsinized fragments of both C-HsCentrins 1 and 2. It was
observed that CK2 phosphorylated centrin 1 on T138 and centrin
2 on T138 and S158.
The sequences of centrins 1 and 2 differ by only three residues
(Fig. 1). The centrin 1 amino acids N131, N158, and E160 are
replaced by K131, S158, and Q160 in centrin 2. The T138 residue
is present in both centrins and surrounded by following three
acidic residues: D139, E140, and E141, which constitute the signa-
ture of a CK2 phosphorylation site. The S158 residue is only found
in centrin 2 and is also surrounded by two acidic residues E159 and
E161.
T138 residue is located within an unstructured loop between
the two a-helices F (residues 124–132) and G (residues 139–
149), and the three acidic residues (D139, E140, E141) are located
at the extremity of the a-helix G. S158 is located at the junction of
calcic loop IV and a-helix H (residues 159–166), and the acidic res-
idues (E159, E161) are located at the extremity of the a-helix H
(Fig. S1B, C).
2.2. Residue 131 is responsible for the different phosphorylation rates
between centrins 1 and 2
The kinetics of CK2 phosphorylation on the C-terminal domains
(M93-Y172) of both centrins 1 (C-HsCen1) and 2 (C-HsCen2) were
performed in parallel in the presence of either EGTA or Ca2+ (Fig. 1A
and B). First, the two isoforms exhibited a different phosphoryla-
tion rate; after 3 h at 37 C, 62% of the C-HsCen1 protein was phos-
HsCen1       MASGFKKPSAASTGQKRKVAPKPELTEDQKQEVREAFDLFDVDGSGTIDAKELKVAMRAL
HsCen2       MASNFKKANMASSSQRKRMSPKPELTEEQKQEIREAFDLFDADGTGTIDVKELKVAMRAL
HsCen3       MSLALRSELLVDKTKRKKRR---ELSEEQKQEIKDAFELFDTDKDEAIDYHELKVAMRAL
*:  ::.   ... ::::     **:*:****:::**:***.*   :** :*********
HsCen1       GFEPRKEEMKKMISEVDREGTGKISFNDFLAVMTQKMSEKDTKEEILKAFRLFDDDETGK
HsCen2       GFEPKKEEIKKMISEIDKEGTGKMNFGDFLTVMTQKMSEKDTKEEILKAFKLFDDDETGK
HsCen3       GFDVKKADVLKILKDYDREATGKITFEDFNEVVTDWILERDPHEEILKAFKLFDDDDSGK
**: :* :: *::.: *:*.***:.* **  *:*: : *:*.:*******:*****::**
HsCen1       ISFKNLKRVANELGENLTDEELQEMIDEADRDGDGEVNEEEFLRIMKKTSLY
HsCen2       ISFKNLKRVAKELGENLTDEELQEMIDEADRDGDGEVSEQEFLRIMKKTSLY
HsCen3       ISLRNLRRVARELGENMSDEELRAMIEEFDKDGDGEINQEEFIAIMTGDI--
**::**:***.*****::****: **:* *:*****:.::**: **.
A B
C D
E F
Fig. 1. Phosphorylation of human centrins 1 and 2 by CK2. Human centrins are aligned using ClustalW program. The sequence analysis shows (⁄) identity, (:) strongly similar,
(.) weakly similar residues. Amino acids are colored in green based on their implication in target binding, in red based on their phosphorylation potentiality. (A, B) The
phosphorylation rate is higher for HsCen1 than for HsCen2. Effect of Ca2+ and implication of the residue 131, on the CK2 access. (C) Ca2+ inhibits the CK2 activity as assessed
using a peptide containing the CK2 signature. (D) Phosphorylation of T138 residue of C-HsCen1 and C-HsCen2. (E, F) Effect of a phosphorylated residue on the
phosphorylation of a second residue. All the kinetics were carried out using the CK2 complex composed of catalytic a and regulatory b subunits. The phosphorylation rate was
determined by the quantiﬁcation of phosphorylated and unphosphorylated forms of centrin after integrating peaks identiﬁed by HPLC separation. In the case of C-HsCen2, the
phosphorylation % corresponded to the sum of the two peaks identiﬁed on HPLC chromatograms. For each graph, the experiments were run in parallel. (For interpretation of
the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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lated. The presence of Ca2+ reduced the phosphorylation rate to
30% and 15% for centrins 1 and 2, respectively; 95% of the C-
HsCen1 protein was phosphorylated after 10 h in the presence of
EGTA, but such a level was only achieved after 48 h in the presence
of Ca2+.
Both HsCen1 and HsCen2 have a different residue at position
131; this residue is N131 in centrin 1 and K131 in centrin 2. Resi-
due 131 is on the surface of the protein and most likely interacts
with CK2; therefore, the K-131 residue could reduce the ability
of CK2 to access centrin (Fig. S1C). This hypothesis was assessed
using site-directed mutagenesis (C-HsCen1-N131K and C-
HsCen2-K131N). The N131K mutation reduced the phosphoryla-
tion of centrin 1 by 30% after 5 h (80% HsCen1 wild type vs. 50%
C-HsCen1N131K) (Fig. 1A). The addition of Ca2+ reduced the phos-
phorylation of centrin 1 by 30% and 40% for C-HsCen1 and C-
HsCen1-N131K, respectively.
The situation was reversed in the case of centrin 2; the K131N
mutation resulted in an increase in phosphorylation by 12% (48%
for C-HsCen2 wild-type vs. 60% for C-HsCen2-K131N) after 5 h
(Fig. 1B). Because the level of phosphorylation corresponded to
the sum of the two sites (T138 and S158), the weak increase in
phosphorylation that was observed demonstrated that the K131
residue had an inhibitory effect on the phosphorylation of the
T138 residue, but not on that of the S158 residue. The presence
of Ca2+ also resulted in a reduction in phosphorylation at the same
extent for the wild type and for the K131N C-HsCen2 proteins. Ca2+
also had an effect on the S158 residue, which is located at the base
of the calcium loop IV.
2.3. Ca2+ inhibits CK2 activity
The peptide ‘‘WELGENTDEELQEMID’’, which is derived from
centrin 1, contains the T138 residue surrounded by the acidic res-
idues that comprise the CK2 phosphorylation site. We tested the
capacity of such a peptide to be phosphorylated by CK2. First, we
observed that the peptide was phosphorylated. The presence of
Ca2+ inhibited its phosphorylation by approximately 20% to 25%,
and 80% of the peptide was phosphorylated at 8 h (Fig. 1C). How-
ever, Ca2+ reduced the phosphorylation of C-HsCen1 by 30% and
80% of the protein was phosphorylated after 48 h (Fig. 1A). The
inhibitory effect of Ca2+ was more evident in the case of centrin
2, where only 50% of the protein was phosphorylated after 48 h
(Fig. 1B). Thus, Ca2+ reduced CK2 kinase activity by acting on the
kinase itself, and Ca2+ also induced changes in the conformation
of centrin, which in turn led to a reduction in its phosphorylation.
Because this phenomenon is more important for centrin 2, we con-
cluded that the S158 residue is most likely more sensitive to Ca2+.
2.4. Relationship between the T138 and S158 phosphorylated residues
By mutating the C-HsCen2 S158 residue to alanine, we reduced
the phosphorylation sites to the unique site T138. We observed
that the rate of phosphorylation of C-HsCen2 T138 was lower than
of C-HsCen1 T138 (Fig. 1D). We investigated the rate of CK2 phos-
phorylation at both T138 and S158 on C-HsCen2. Using the S158A
variant, we determined the rate of phosphorylation of the T138
residue; conversely, using the T138A variant, we determined the
phosphorylation of the S158 residue. Under these conditions, we
observed that the T138 residue exhibited a 20% increase of the
phosphorylation rate compared with the S158 residue (Fig. 1E
and F).
The presence of Ca2+ reduced the phosphorylation rate of both
T138 and S158 but the reduction at S158 was more prominent
by a factor of 2.7 compared with the reduction at T138 which
was a factor of 1.8.We also investigated the effect of phosphorylation by CK2 at
one site on the phosphorylation at the other site (Fig. 1E and F).
The phosphomimetic mutation T138D had no effect on the rate
of phosphorylation of S158 even in the presence of Ca2+. However,
the C-HsCen2-S158D exhibited a reduced phosphorylation rate at
T138 by a factor of 1.36, and the presence of Ca2+ increased this
reduction by a factor of 2.1.
2.5. Human centrin 1 binds transducin b whose hydrophobic triad has
a speciﬁc composition
The three human transducin b isoforms (b1, code P62873; b2,
code P62879; b3, code P16520) are composed of 340 amino acids
and contains seven WD repeats; the ﬁnal WD repeat (M325AVA-
TGSWDSFLKIWN340) is identical for the three isoforms and is
located at the C-terminus. This speciﬁc WD repeat was designated
as a potential centrin-binding target based on comparisons to the
Sﬁ1 and XPC motifs. We analyzed the capacity of centrin to bind
one of the seven WD motifs (S74QDGKLIIWDSYTTNKV90) of trans-
ducin b1 (Fig. S2) (Fig. S5), and observed that this peptide did
not bind centrin (Fig. S2). We further analyzed the capacity of C-
HsCen1 to bind the transducin b-derived peptide (MAV-
ATGSWDSFLKIWN340), which appeared to have the potential to
bind to centrin. We observed that this peptide bound centrin but
only in the presence of Ca2+ (Fig. 2). The binding reaction occurred
with an exothermic heat exchange (negative enthalpy) and a 1:1
stoichiometry. The experimental data could be best ﬁt into a
one-site binding model with an equilibrium association constant
Ka = 0.54 106 M1. We observed the same binding behavior using
the full-length centrin 1 (Fig. 3), and Ca2+ was absolutely required
for the binding of transducin b1, but the binding constant was
weak (Ka = 0.17 106 M1).
R18-Sﬁ1 showed an afﬁnity weaker than XPC in the presence of
EDTA (Fig. 2). Reversing the sequence orientation of R17-Sﬁ1, (R17-
Sﬁ1inv Table 1), increased its afﬁnity for centrin 1 by nearly 10-
fold in the absence of Ca2+. This mutation also increased the change
in enthalpy (DH: 43 kcal/mole to 26 kcal/mole), which was
accompanied by an increase in the change in entropy (TDS:
36 kcal/mole to 18.42 kcal/mole) (Table 2).
Several peculiarities were observed for the centrin-binding site
of transducin b. These included the unusual presence of W332 at
position 8 of the hydrophobic triad and the presence of the acidic
residue D333 at position 7, where a basic residue is usually found
in other centrin targets. Two point mutations, W332L and D333R,
were analyzed (Table 2). The W332L mutation did not signiﬁcantly
change the afﬁnity of Trd for C-HsCen1, which was similar to what
was observed for full-length centrin 1. The Trd-D333R variant
showed a small increase in afﬁnity for centrin. However, the dou-
ble mutation (Trd-W332L-D333R) increased the afﬁnity of trans-
ducin b for centrin by almost a factor of 100 in the presence of
Ca2+ (Table 2). Additionally, binding of TrdW332L-D333R to C-
HsCen1 occurred in the presence of EDTA with an afﬁnity constant
of 0.1 106 M1 which is only 5-fold lower than the afﬁnity constant
observed for wild type transducin b in the presence of Ca2+
(0.54 106 M1). We also observed an increase in the change in
enthalpy by a factor of 2 for the double mutant as well as an
increase in the afﬁnity. Thus, the double mutation W332L-D333R
has a centrin binding behavior similar to Sﬁ1.
2.6. Phosphorylation at the T138 residue of centrin 1 abolishes the
binding of transducin b
CK2 phosphorylation of centrin 1 at T138 abolished its ability to
bind transducin b (Fig. 3). Additionally, the T138D phosphomimet-
ic mutation had no effect on the binding of centrin 1 to transducin
b whereas direct phosphorylation by CK2 did. However, the
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Fig. 2. Effect of the orientation of the centrin-binding motif on the target binding to C-HsCen1 as measured by ITC. The ITC measurements show the C-HsCen1 binding to
several targets: Trd b (centrin-binding motif), P17-XPC, R18-Sﬁ1, R17-Sﬁ1, and R17-Sﬁ1 inv. The upper panels show the raw data, and the lower panels show the binding
isotherms ﬁtted to a one-site model. Peptide solutions (100 lM) were injected into the protein (10 lM) equilibrated in buffer (MOPS 50 mM, NaCl 100 mM, EDTA 2 mM or
CaCl2 1 mM, pH 7.5) at 30 C in the calorimeter cell.
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energy (DG) remained constant; also, the change in enthalpy (DH)
increased by a factor of 5, resulting in a less negative and therefore
less favorable value (Table 3). Glutamate residues have longer side
chains than aspartate residues, and are more similar to phosphose-
rines; however, aspartate is more similar to unphosphorylated
serine. Because threonine residues are longer than serine residues,
glutamate is the best candidate to mimic the phosphorylation of a
threonine residue. Therefore, the second variant T138E was con-
structed only for the C-terminal domain for HsCen1 (C-HsCen1-
T138E), and this mutation more efﬁciently mimicked the phos-
phorylation than the C-HsCen1-T138D construct. The results show
that the T138E mutation decreased the afﬁnity of centrin 1 for
transducin b by a factor of 7 (Fig. S3).
Because the transducin motif contains a W residue at position 8,
which is commonly occupied by an L residue in other centrintargets (XPC and Sﬁ1), we also used the mutated transducin b
peptide W332L. This mutated peptide showed results similar to
the wild type Trd- (Table 3). Thus, there was no binding between
the transducin b-derived peptide and centrin 1, which was phos-
phorylated by CK2. However, HsCen1-T138D still bound to the
transducin b W332L peptide with a binding constant reduced by
half with similar enthalpy and entropy changes.
2.7. Phosphorylation at T138 of centrin 1 has a weak effect on centrin
binding to XPC
XPC is a protein consisting of 940 amino acids and contains only
one centrin-binding hydrophobic triad W848xxL851xxxL855, which
is located at the C-terminus. However, this motif is in the opposite
orientation compared to the centrin-binding motif found in
transducin b.
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Fig. 3. Regulation by CK2 phosphorylation of the centrin 1 binding to tranducin b and to P17-XPC as measured by ITC. The ITC measurements show the Trd and XPC binding to
centrin 1 (unphosphorylated, phosphorylated centrin, and T138D phosphomimetic). For each graph, the upper panels show the raw data, and the lower panels show the
binding isotherms ﬁtted to a one-site model. Peptide solutions (100 lM) were injected into the protein (10 lM) equilibrated in buffer (MOPS 50 mM, NaCl 100 mM, EDTA
2 mM or CaCl21 mM, pH 7.5) at 30 C in the calorimeter cell.
Table 1
Peptides used for ITC experiments.
HsTrBWD: 74-SQDGKLIIWDSYTTNKV-90
HsTrB: 325-MAVATGSWDSFLKIWN-340
HsTrBW332L: 325-MAVATGSLDSFLKIWN-340
HsTrBD333R: 325-MAVATGSWRSFLKIWN-340
HsTrBW332L-D333R: 325-MAVATGSLRSFLKIWN-340
HsSfiR18: 677-SQHNRQLLRGALRRWK-692
HsSfiR17: 641-RADLHHQHSVLHRALQAWVT-660
HsSfi1R17inv: 660-TVWAQLARHLVSHQHHLDAR-641
P17-XPC : 846-NWKLLAKGLLIRERLKR-863
CEN1Pa: W131-ELGENLTDEELQEMID-147
a A tryptophan residue was added at the N-terminus for UV measurement.
412 D. Grecu, L. Assairi / FEBS Open Bio 4 (2014) 407–419Contrary to transducin b, the binding of centrin to XPC did not
require Ca2+, although the presence of Ca2+ increased the binding
by a factor of 5 (Table 3). Phosphorylation at T138 reduced bindingto XPC in the presence of EDTA by a factor of 10 (Fig. 3). The T138D
phosphomimetic mutation reduced the binding to XPC by a factor
of 4 in the presence of EDTA (Fig. 3). However, the T138D mutation
did not completely mimic the phosphorylation. Therefore, we
investigated the second C-HsCen1-T138E, and this mutation more
efﬁciently mimicked the phosphorylation compared with the C-
HsCen1-T138D construct (Fig. S3). The T138E mutation decreased
the afﬁnity of centrin 1 for XPC by a factor of 20 in the presence
of EDTA, whereas the T138D mutation decreased the afﬁnity for
XPC by a factor of 2. However, the enthalpy was unchanged, and
the entropy slightly increased to 4 kcal/mole in the presence of
EDTA, leading to a reduction in free energy by 2 kcal/mole.
Contrary to transducin b, phosphorylation of centrin 1 at T138
weakly affected XPC binding. The centrin-binding motif of both
XPC and transducin b are in opposite orientations, and this situa-
tion is most likely the cause for the centrin-speciﬁc phosphoryla-
tion effect observed.
Table 2
Thermodynamic parameters of C-HsCen1 binding to Trd, P17-XPC, R17- and R18-Sﬁ1.
Protein Ligand Ca2+ N Ka (error) (106 M1) DH (error) (kcal/mol) TDS (kcal/mol) DG (kcal/mol)
C-HsC1 Trd + 1.2 0.54 (0.3) 9.57 (0.13) 1.62 7.95
 NB NB NB NB NB
C-HsC1 P17-XPC + 0.93 39.6 (0.15) 23.27 (0.05) 12.73 10.54
 1.05 8.25 (4.3) 28.1 (0.13) 18.57 9.53
C-HsC1 R18-Sﬁ1 + 0.99 81.5 (78) 22.5 (0.087) 11.51 10.99
 1.03 3.56 (1.3) 29.8 (0.12) 20.75 9.05
C-HsC1 R17-Sﬁ1 + 1.21 125 (126) 18.0 (0.06) 6.79 11.21
 0.88 0.12 (0.09) 43.1 (2.6) 36.06 7.04
C-HsC1 R17inv-Sﬁ1 + 0.80 149 (142) 21.57 (0.08) 10.21 11.36
 0.825 0.69 (0.3) 26.55 (0.34) 18.42 8.13
C-HsC1 TrdW332L + 0.85 0.85 (0.8) 13.82 (0.03) 5.57 8.25
 NB NB NB NB NB
C-HsC1 TrdD333R + 1.2 1.7 (0.5) 12.09 (0.06) 3.42 8.67
 NB NB NB NB NB
C-HsC1 TrdW332L-D333R + 0.94 20 (9.3) 18.93 (0.06) 8.82 10.11
 1.19 0.10 (0.09) 9.8 (0.64) 2.82 6.15
The ITC experiments were conducted at 30 C in buffer (MOPS 50 mM, NaCl 100 mM, EDTA 2 mM or CaCl21 mM, pH 7.5). N was the stoichiometry of binding. The standard
deviations of the ﬁtted parameters are given in parenthesis.
Table 3
Thermodynamic parameters of HsCen1 and C-HsCen1 binding to Trd, P17-XPC, R17- and R18-Sﬁ1.
Protein Ligand Ca2+ N Ka (error) (106 M1) DH (error) (kcal/mol) TDS (kcal/mol) DG (kcal/mol)
HsC1 Trd + 0.83 0.17 (0.12) 12.23 (0.5) 4.97 7.26
– NB NB NB NB NB
HsC1P Trd + NB NB NB NB NB
 NB NB NB NB NB
HsC1T138D Trd + 0.75 0.18 (0.26) 8.14 (0.7) 0.85 7.29
 NB NB NB NB NB
C-HsC1 Trd + 1.2 0.54 (0.3) 9.57 (0.013) 1.62 7.95
 NB NB NB NB NB
C-HsC1T138D Trd + 1.15 0.2 9.97(0.4) 2.62 7.35
C-HsC1T138E Trd + 1.18 0.073 10.0(0.4) 3.03 6.97
HsC1 TrdW332L + 0.78 0.13 (0.13) 10.6 (0.8) 3.5 7.1
 NB NB NB NB NB
HsC1P TrdW332L + NB NB NB NB NB
 NB NB NB NB NB
HsC1T138D TrdW332L + 0.76 0.06 (0.15) 12.16 (3.7) 5.5 6.66
 NB NB NB NB NB
HsC1 P17-XPC + 1.04 52.5 (23) 28.44 (0.08) 17.72 10.72
 0.98 12.2 (2.7) 28.43 (0.05) 18.6 9.83
HsC1P P17-XPC + 0.58 46.2 (25) 34.57 (0.11) 23.94 10.63
 0.61 0.84 (0.24) 30.45 (0.27) 22.21 8.24
HsC1T138D P17-XPC + 0.95 102 (103) 28.47 (0.11) 17.36.21 11.11
 0.92 2.9 (0.6) 30.17 (0.08) 21.18 8.99
C-HsC1 P17-XPC + 0.93 39.6 (0.15) 23.27 (0.05) 12.73 10.54
 1.05 8.25 (4.3) 28.1 (0.13) 9.57 9.53
C-HsC1T138D P17-XPC + 0.86 33.4 (1.9) 23.6 (0.07) 13.18 10.43
 0.93 4.55 (0.12) 30.19 (0.08) 20.93 9.26
C-HsC1T138E P17-XPC + 1.01 9.03 (0.83) 21.22 (0.16) 11.57 9.65
 0.93 0.43 (0.02) 32.56 (0.61) 24.72 7.84
HsC1 R18-Sﬁ1 + 0.88 249 (345) 35.49 (0.14) 23.81 11.68
 0.88 3.47 (0.7) 34.70 (0.09) 25.66 9.04
HsC1P R18-Sﬁ1 + 0.65 85.6 (78) 39.40 (0.16) 28.48 10.92
 0.57 0.258 (0.1) 42.96 (1.60) 35.45 7.51
HsC1T138D R18-Sﬁ1 + 0.77 239 (307) 36.73 (0.14) 25.09 11.64
 0.83 0.875 (0.2) 36.44 (0.20) 28.18 8.26
HsC1 R17-Sﬁ1  1.12 0.347 (0.2) 19.25 (0.37) 11.57 7.68
HsC1P R17-Sﬁ1  NB NB NB NB NB
The ITC experiments were conducted at 30 C in buffer (MOPS 50 mM, NaCl 100 mM, EDTA 2 mM or CaCl21 mM, pH 7.5). N was the stoichiometry of binding. NB means no
binding. The standard deviations of the ﬁtted parameters are given in parenthesis.
D. Grecu, L. Assairi / FEBS Open Bio 4 (2014) 407–419 4132.8. Phosphorylation of centrin 1 at T138 reduced its binding to Sﬁ1
We investigated the effects of centrin 1 phosphorylation on
ability to bind to human Sﬁ1, another centrin target that is
1242 amino acids in length. Sﬁ1 contains 25 centrin-binding sites,
which are in the same orientation as the centrin-binding site of
transducin b. Similarly to P17-XPC, R18-Sﬁ1 (Table 1), bound to
centrin 1 in the absence of Ca2+ (Fig. 4), although the presence
of Ca2+ did increase its binding. The binding reaction took placewith an exothermic heat exchange (negative enthalpy) and
a 1:1 stoichiometry; the one-site binding model gave an
equilibrium association constant Ka = 3.5 106 M1 and 2.5 108 M1
in the absence and presence of Ca2+, respectively (Table 3).
Phosphorylation of centrin 1 at T138 reduced the ability of the
protein to bind to R18-Sﬁ1 by a factor of 10 in the absence or
in the presence of Ca2+.
Because HsSﬁ1 has 25 homologous but not identical centrin-
binding sites, we also investigated another Sﬁ1-repeat, R17-Sﬁ1
414 D. Grecu, L. Assairi / FEBS Open Bio 4 (2014) 407–419(Table 1) (Fig. 4). The binding constant of HsCen1 to R17-Sﬁ1
decreased by a factor of 10 in the absence of Ca2+ compared with
R18-Sﬁ1 (Table 3). The change in enthalpy was reduced and
accompanied by an increase in entropy by a factor of 2. Phosphor-
ylation at T138 abolished the binding of centrin 1 to R17-Sﬁ1 in the
absence of Ca2+.
2.9. The T138D and S158D phosphomimetics of centrin 2 exhibited
reduced binding to XPC
The effect of the two T138D and S158D singlemutations (Fig. S4)
as well as the T138D-S158D double mutation on binding of centrin
2 to XPC was analyzed in the absence of Ca2+ (Fig. 5). The T138D
mutation reduced the afﬁnity for P17-XPC by a factor of 3 and
increased the negative enthalpy by a factor of 1.7; the S158Dmuta-
tion reduced the afﬁnity for XPC by a factor of 3.7 but the enthalpy
stayed the same. However, the T138D-S158D double mutation
reduced the afﬁnity by a factor of 9 and slightly increased theHsCen1
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Fig. 4. Regulation by CK2 phosphorylation of the centrin 1 binding to Sﬁ1 as measured b
centrin and T138D phosphomimetic) binding to R18-Sﬁ1 and R17-Sﬁ1. The upper panels
site model. Peptide solutions (100 lM) were injected into the protein (10 lM) equilib
calorimeter cell. Human Sﬁ1 centrin-binding motifs, the residues composing the hydropnegative enthalpy. Clearly, phosphorylation at S158 acted in con-
cert with phosphorylation at T138 to reduce the binding of centrin
2 to P17-XPC. However, the T138D-S158D double mutation did not
completely abolish the binding of centrin 2 to P17-XPC.
In the presence of Ca2+ (Table 4), the T138D mutation reduced
afﬁnity of centrin 2 to XPC by a factor of 2 but the S158D mutation
exhibited a smaller reduction of the afﬁnity. The T138D-S158D
double mutation reduced the afﬁnity for XPC by a factor of 2 as
the T138D mutation. The three variants exhibited an identical
enthalpy and entropy.
2.10. The T138D-S158D phosphomimetic of centrin 2 does not bind to
R17-Sﬁ1 in the absence of Ca2+
In the absence of Ca2+ (Fig. S4), the T138D phosphomimetic
mutation had no effect on the afﬁnity to R17-Sﬁ1 but induced a
strong decrease of the negative enthalpy and a strong decrease of
the negative entropy because of the unfavorable binding. TheCen1-P
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y ITC. The ITC measurements show the HsCen1 (unphosphorylated, phosphorylated
show the raw data, and the lower panels show the binding isotherms ﬁtted to a one-
rated in buffer (MOPS 50 mM, NaCl 100 mM, EDTA 2 mM, pH 7.5) at 30 C in the
hobic triad are underlined (bottom left).
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Fig. 5. Regulation by CK2 phosphorylation of the centrin 2 binding to P17-XPC and R17-Sﬁ1 as measured by ITC. The ITC measurements show the HsCen2 (unphosphorylated
and T138D-S158D phosphomimetic) binding to P17-XPC and R17-Sﬁ1. The upper panels show the raw data, and the lower panels show the binding isotherms ﬁtted to a one-
site model. Peptide solutions (100 lM) were injected into the protein (10 lM) equilibrated in buffer (MOPS 50 mM, NaCl 100 mM, EDTA 2 mM, pH 7.5) at 30 C in the
calorimeter cell.
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almost identical enthalpy, but the negative entropy increased as
a consequence of unfavorable binding. In contrast to XPC, the
T138D-S158D double mutation abolished the binding of centrin 2
to R17-Sﬁ1 (Fig. 5).
In the presence of Ca2+ (Table 4), the T138D mutation increased
the afﬁnity for R17-Sﬁ1 by a factor of 3, and the S158D mutation
increased the afﬁnity by a factor of 5; both of these variants had
an enthalpy almost identical to the wild type protein under similar
conditions. The S158Dmutation increased the afﬁnity by a factor of
5 with an almost identical enthalpy. The T138D-S158D double
mutation increased the afﬁnity by a factor of 2 with the same
enthalpy. For the three variants, the negative entropy increased
by a factor of 2.3. Discussion
3.1. Centrins bind several targets the centrin-binding motif of which
exists in the two orientations
An important feature of the interaction between centrin and
its targets is that the centrin-binding motif exists in both
orientations (i.e., WxxLxxxL for XPC and LxxxLxxW for Sﬁ1,
transducin b and Sac3). The NMR structures of C-HsCen2 in com-
plex with either the XPC-derived peptide [19] or Sﬁ1-derived
peptide [20] showed that the E148 residue binds XPC but not
Sﬁ1. Further site-directed mutagenesis of the homologue of the
E144 residue from the Scherffelia dubia illustrated this target
speciﬁcity [29].
Table 4
Thermodynamic parameters of C-HsCen2 binding to P17-XPC and R17-Sﬁ1.
Protein C-HsC2 Ligand Ca2+ N Ka (error) (106 M1) DH (error) (kcal/mol) TDS (kcal/mol) DG (kcal/mol)
WT P17-XPC + 0.81 52.7(2.3) 23.4(0.06) 12.7 10.7
 0.95 7.35(0.2) 29.3(0.09) 19.75 9.55
T138D P17-XPC + 0.82 27.1(1.7) 24(0.09) 13.7 10.31
 0.94 2.5(0.04) 32.7(0.08) 23.88 8.82
S158D P17-XPC + 0.89 43.1(1.9) 23(0.05) 12.63 10.37
 1.181.0.7 2.02(0.1) 23.8(0.03) 15.03 8.77
T138D-S158D P17-XPC + 1.18 29.0(1.7) 23.9(0.08) 13.6 10.3
 0.8(0.02) 26.8(0.15) 18.6 8.2
WT R17-Sﬁ1 + 0.95 18.2(0.8) 20.2(0.06) 6.12 14.08
 0.72 0.19(0.0) 31.3(0.09) 23.97 7.33
T138D R17-Sﬁ1 + 0.86 45.4(2.1) 24.3(0.06) 13.66 10.64
 0.75 0.23(0.04) 9.76(0.09) 2.31 7.45
S158D R17-Sﬁ1 + 0.7 101(7.3) 25.9(0.008) 14.76 11.14
 0.77 0.04(0.01 38.5(22.3) 32.12 6.38
T138D-S158D R17-Sﬁ1 + 0.91 35(2.6) 22.4(0.09 11.88 10.52
 NB NB NB NB NB
0.91 24.9(0.9) 20.15(0.05) 9.94 10.21
WT R17inv + 1.09 0.36(0.03) 21.96(0.7) 14.24 7.72
The ITC experiments were conducted at 30 C in buffer (MOPS 50 mM, NaCl 100 mM, EDTA 2 mM or CaCl21 mM, pH 7.5). N was the stoichiometry of binding. The standard
deviations of the ﬁtted parameters are given in parenthesis.
416 D. Grecu, L. Assairi / FEBS Open Bio 4 (2014) 407–4193.2. Three targets (XPC, Sﬁ1 and transducin b) bind centrin with
various afﬁnities and different levels of Ca2+-dependence
A centrin-binding site was identiﬁed in the C-terminus of trans-
ducin b, and it was recorded as the last WD motif. We recognized
the characteristic hydrophobic triad of the centrin-binding motif,
and tested this triad for centrin binding using ITC; we also tested
the binding of centrin to another WD motif found in transducin b
and observed no interaction. By contrast, the last WD motif was
observed to bind centrin exclusively in the presence of Ca2+,
although its afﬁnity was lower than the afﬁnity observed for other
centrin targets (XPC and Sﬁ1). Interactions between murine
centrins and transducin have previously been demonstrated by
co-immunoprecipitation and centrifugation assays [13]. Here, we
corroborated these results and showed that human centrins also
bind to transducin b. Moreover, using the ITC method, we assessed
the mechanism of interaction between centrin and transducin b at
the molecular level. Some peculiarities were observed with trans-
ducin b. First, centrin had a very weak binding afﬁnity for trans-
ducin b. The observed Ka was 0.15 106 M1, 249 106 M1 and
52.5 106 M1 for Trd, R17-Sﬁ1 and P17-XPC respectively. Addition-
ally, the presence of Ca2+ was absolutely required for this interac-
tion to occur. The presence of a W residue in position 8 of the
hydrophobic triad is unusual compared to the other centrin-targets
that is, XPC, Sﬁ1, and Sac3. Indeed, among the 25 centrin-binding
motifs identiﬁed in human Sﬁ1, none of these motifs has a W res-
idue at position 8. However, a W residue at position 4 can be found
in 7 centrin-binding motifs in human Sﬁ1 (Fig. S5). The presence of
an acidic residue, such as D, in place of the basic R residue at posi-
tion 7 is also unusual, though this substitution is strongly con-
served among GNB proteins (Fig. S2).
3.3. Phosphorylation of human centrins 1 and 2 by CK2
CK2 is a serine/threonine protein kinase; however, it can phos-
phorylate tyrosine residues in mammalian cells [30]. In our exper-
iments, we used the complex composed of two catalytic subunits
(b) and two regulatory subunits (b) and succeeded in phosphory-
lating human centrins 1 and 2. HsCen1 was phosphorylated at
one unique site, T138, which is surrounded by three acidic residues
(D, E, E) based on the CK2 signature. The T138 residue is conserved
among centrins, except for in human HsCen3 where it is replaced
by a serine residue (Fig. 1). Because the S138 residue of HsCen3is also surrounded by acidic residues, this site could still be a
potential CK2 phosphorylation site. In contrast, C-HsCen2 was
phosphorylated at both T138 and S158 residues. The S158 residue
is also surrounded by two acidic E residues. However, this site is
absent in human centrins HsCen1 and HsCen3, as well as in
Cdc31 and centrin in S. dubia. Because HsCen1 is derived from a
retrotransposition of HsCen2, the S158 residue most likely
emerged after the appearance of HsCen1, and consequently, the
N158 residue found at this position in other centrins is most likely
the ancestral residue. An equivalent of the S158 residue of HsCen2
is found in primates as well as some ﬁshes and birds (Fig. S6B).
The phosphorylation events of centrins 1 and 2 by CK2 as well
as the co-localization of CK2 and centrin 1 and 2 in the connecting
cilium have already been demonstrated [27]. However, several dif-
ferences were observed between murine and human centrins. In
mice, Cen1 and Cen2 are also phosphorylated at the T138 residue,
although very weak phosphorylation of Cen3 has been observed.
This is most likely due to the presence of R131, which could restrict
CK2 from accessing the centrin, as we observed for K131 (Fig. S6A).
Additionally, the S158 residue is absent in murine Cen2.
3.4. Phosphorylation by CK2 regulates the binding of human centrins
to their targets (XPC, Sﬁ1 and transducin b
It was previously demonstrated that CK2-phosphorylation
reduced the binding of murine centrins to transducin [27]. Our
results showed that the CK2-phosphorylation of human centrin 1
completely abolished its ability to bind transducin b and reduced
the binding of centrin 1 to other targets. In other studies, CK2-
phosphorylation has the opposite consequences and enhances
the binding of a protein to its target, as in the case of CLIP-170,
which interacts with the kinetochore-microtubule upon CK2 phos-
phorylation [31].
The structure of transducin bc in complex with phosducin has
been solved by X-ray crystallography [32,24]. The transducin b res-
idues that interact with phosducin are located outside of the cen-
trin-binding site. However, the W332 residue of transducin b,
which is part of the centrin-binding motif, establishes contacts
with three residues (M101, H102 and L105) located in helix 3 of
phosducin. Fig. S5 shows that the residues comprising the hydro-
phobic triad that binds centrin 1 are located in the last b-sheet at
the C-terminus of transducin b. This clearly shows that the cen-
trin-binding motif is completely embedded within the transducin
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ing motif. Therefore, we believe that when phosducin interacts
with transducin bc, centrin cannot bind to transducin b.
Our experiments demonstrated that the binding of centrin to
transducin is regulated by the phosphorylation of centrin. Addi-
tionally, the binding of phosducin to transducin is also regulated
by phosphorylation. Phospho-phosducin, which is phosphorylated
at S73 by PKA, cannot form a complex with transducin. Modeling
experiments have shown that the phosphate group sterically and
electrostatically clashes with the downstream residues in helix 2
particularly N75 and E76, thereby leading to the disruption of
transducin abc binding.
3.5. Relationship between phosphorylation and Ca2+-dependence of
HsCen1 and HsCen2
For XPC, whose the binding to centrin is Ca2+-independent, the
phosphorylation at T138 has a little effect. However, the phosphor-
ylation at S158, which exists in HsCen2, reduced the binding of XPC
to HsCen2. Thus if HsCen2 is the natural isoform which binds XPC,
phosphorylation at both T138 and S158 could regulate its binding
to XPC. However, the double phosphomimetic T138D-S158D did
not abolish the binding of HsCen2 to XPC, as there was a residual
binding capacity of HsCen2 to XPC.
3.6. Phosphorylation of centrin could induce its conformational change
Conformational changes of phosphorylated proteins have been
assessed using X-ray crystallography [33], NMR [34], hydrogen/
deuterium exchange mass spectrometry (DXMS) [35] and molecu-
lar dynamics (MD) simulations [36].
Phosphorylation of a protein can either induce or prevent the
binding of another molecule. Several examples have been reported
in literature showing that phosphorylation of a protein induces the
formation of complexes; here we report the results of four of these
complexes. The ﬁrst example concerns Elk-1, an eukaryotic tran-
scription factor whose phosphorylation induces a conformational
change that promotes its binding to DNA [37]. The second example
involves Bcl-2, a central regulator in the mitochondrial-mediated
apoptosis pathway. The phosphorylation of a disordered loop of
Bcl-2 induces its conformational change and allows for consequent
binding of Pin1 [38]. The third example concerns the Staphylococ-
cus aureus protein VraR (a vancomycin-resistance-associated
response regulator), whose phosphorylation promotes the dimer-
ization of its DNA-binding domains [33]. X-ray crystal structures
of VraR in both the unphosphorylated and berylloﬂuoride-acti-
vated state (which mimics the phosphorylated VraR) have been
solved. The ﬁnal example concerns the IIA-IIB complex of the
N,N0-diacetylchitobiose transporter of the Escherichia coli phospho-
transferase system which has been solved by NMR [34].
The phosphorylated residue can either be situated at the inter-
face of the two partners or somewhere else in the protein. How-
ever, in the second case, the phosphorylation outside of the
interface induces conformational changes, which consequently
make that the target interface inaccessible to the binding partner.
Phosphorylation at the interface of the protein complex is illus-
trated by Erbin, which binds the C-terminus of the receptor tyro-
sine kinase ErbB2. The crystal structure of the PDZ domain Erbin
in complex with an ErbB2-derived peptide, which contains a tyro-
sine residue, has been solved [39]. Phosphorylation of the ErbB2
tyrosine residue abolishes its binding to Erbin.
Two other examples illustrate the phosphorylation outside the
interface of the partners. The ﬁrst example concerns Cdc34-like
enzymes, which catalyze the formation of polyubiquitin chains
on several proteins [40]. Cdc34 contains an acidic loop whose con-
formation is modulated by CK2 phosphorylation of two residuesS130 and S167. The authors analyzed other Cdc34-like enzymes
and showed that there is a co-evolution of the phosphorylation
sites and the acidic loop with regard to the proximity of the active
site in Cdc34-like enzymes. Using multiple molecular dynamics
(MD) simulations, the author investigated the conformational
changes of the acidic loop which is characterized by a high confor-
mational variability and some residues of the acidic loop were
transiently close to the catalytic cleft. The authors hypothesized
that phosphorylation of S130 situated outside of the acidic loop
introduced a strong negatively charged group, which may result
in electrostatic repulsion from the acidic loop. The second example
concerns Rap1b, which is involved in the transduction of the
cAMP-mitogenic response [35]. Rap1b is a GTPase that regulates
the transduction of external stimuli. The S179 residue is situated
at the extremity of a polybasic segment facing an acidic loop
(D47 and E45), which connects 2 beta sheets also connected to
the switch loops that interact with the nucleotide. The effect of
the PKA-phosphorylation Ser179 on the conformational changes
of Rap1 was analyzed using hydrogen/deuterium exchange mass
spectrometry. Higher exchange was observed in both the phos-
phorylated and phosphomimetic state compared with the non-
phosphorylated state of Rap1. Phosphorylation of S179 incorpo-
rates a repulsive negative charge that reﬂexively rotates the facing
acidic loop and causes additional rotation of the switch loops.
In the case of centrin, CK2-phosphorylation also occurs outside
the centrin hydrophobic cavity where the target protein normally
binds. Based on the Cdc34 and Rap1 studies reported above, we
propose a mechanism by which phosphorylation could regulate
the binding capacity of the C-HsCen to its targets. Thus, phosphor-
ylation of T138 could induce the repulsion of the acidic segment
(E159, E160, E161) connected to the Ca2+ loop IV would conse-
quently be oriented in such a way that it cannot bind calcium any-
more. Furthermore, any Ca2+-dependent regulation would
effectively be eliminated.
4. Materials and methods
4.1. Chemicals, bacterial strains, plasmids
The peptides used in this study were purchased from GENE-
CUST, and all the peptides were acetylated at their N-terminus
and amidated at their C-terminus to increase their stability.
Oligonucleotides were purchased from Eurogentec; dNTPs, NdeI
and XhoI restriction enzymes, T4 DNA ligase, and Finnzymes
Phusion DNA polymerase were purchased from New England
Biolabs. The pET24 vector and E. coli NM554 and Bl-21(DE3) strains
were purchased from Novagen. DEAE-TSK and phenyl-TSK were
purchased from Interchim. Sephadex G25 was purchased from
GE-Healthcare.
4.2. Cloning of human centrins 1, 2 and site-directed mutagenesis
The human centrin 1 coding sequence was ampliﬁed from a
clone (a gift from Bornens) via polymerase chain reaction (PCR)
using Phusion DNA polymerase, dNTPs, and the ﬂanking primers
50-C1 (50-GGAATTCCATATGGCTTCCGGCTTCAAGAAG-30) and 30-C1
(50-CGGCGCTCGAGTCAGTAAAGGCTGGTCTTCTTCAT-30) to create
plasmid pLA11.33.2 encoding full-length centrin 1. Site-directed
mutagenesis was accomplished via the double PCR method [41],
using a wild type clone as the template, containing dNTPs, and
Phusion DNA polymerase both ﬂanking 50- and 30-primers listed
above and the following mutagenic oligonucleotides: for
pLA11.33.20 encoding Cen1-T138D 30-C1T138D (50-CTGCAGCTCC
TCATCATCGAGGTTCTCCCCCAG-30); for pLA11.33.38 encoding
Cen1-T138E 30-C1T138E (50-CTGCAGCTCCTCATCTTCGAGGTTCTC
CCCCAG-30); for pLA11.33.25 encoding Cen1-N131K 30-C1N131K
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nal domain of centrin 1 (wild type and variants) was generated
using the above plasmids (full-length) and the ﬂanking primers,
50-C1M93 (50-GGAATTCCATATGACGCAGAAGATGTCCGA-30) or 50-
C1M97 (50-GGAATTCCATATGTCCGAGAAGGACACCAAAGAAG-30)
and 30-C1, resulting in the following plasmids: pLA11.33.23 (C-
Cen1-M93-Y172), pLA11.33.5 (C-Cen1-M97-Y172), pLA11.33.32
(C-Cen1-T138D), pLA11.33.39 (C-Cen1-T138E), and pLA11.33.25
(C-Cen1-N131K).
Full-length centrin 2 and the C-terminal domain (M93-Y172)
were obtained from [19]. Site-directed mutagenesis of centrin 2
was accomplished as above using centrin 2 wild-type full-length
and ﬂanking primers 50-C2 (50-GGAATTCCATATGGCCTCCAACTT
TAAGAAGG-30), 30-C2 (50-CGGCGCTCGAGTTAATAGAGGCTGGTCTT
TTTCAT-30), and 30- primers listed above and the following muta-
genic oligonucleotides: for pLA11.37.12 encoding Cen2-K131N 30-
C2K131N (50-GTTCTCACCCAACTCGTTGGCCACGCGTTTCAG-30), for
pLA11.37.8 encoding C2T138D 30-C2T138D:50-CTGCAGCTCCTCATC
ATCCAGGTTCTCACCCAA-30; for pLA11.37.13 encoding C2T138A 30-
C2T138A: 50-CTGCAGCTCCTCATCAGCCAGGTTCTCACCCAA-30; for
pLA11.37.14 encoding C2S158D 30-C2S158D: 50-CAGGAACTCTTGC
TCATCGACCTCTCCATCTCC-30; for pLA11.37.15 encoding C2S158A
30-C2S158A: 50-CAGGAACTCTTGCTCAGCGACCTCTCCATCTCC-30;
for pLA11.37.28 encoding C2T138D-S158D, pLA11.37.14 encoding
C2S158D was used as template with 30-C2T138D mutagenic
oligonucleotide.
The C-terminal domain of all centrin 2 mutants were generated
by PCR using the above plasmids (full-length) mutants as tem-
plates and the ﬂanking primers 50-C2M93 50-GGAATTCCATATGACC
CAGAAAATGTCTGAGAAA-30 and 30-C2 resulting in the following
plasmids: pLA11.37.17 (encoding C-Cen2-K131N), pLA11.37.18
(encoding C-C2-T138D), pLA11.37.30 (encoding C-Cen2-T138A),
pLA11.37.19 (encoding C-C2-S158D), pLA11.37.20 (encoding
C-Cen2-S158A), pDAG1.1.1 (encoding C-C2-T138D-S158D),
pLA11.37.32 (encoding C-Cen2T138A-S158A).
All the PCR products were digested with the NdeI and XhoI
restriction enzymes, and T4 DNA ligase was used to insert the
mutated genes between the NdeI and XhoI restriction sites of the
pET24a expression vector. The resulting plasmids were used to
transform the E. coli NM554 strain, and the transformed clones
were sequenced to verify their integrity and the incorporation of
the desired mutation. DNA from successfully transformed clones
was isolated and used to transform E. coli strain BL21(DE3)/pDIA17
cells, which are chloramphenicol resistant, in order to express the
recombinant proteins.
4.3. Expression and puriﬁcation of human centrins 1, 2 from E. coli
To overproduce centrins 1 and 2, bacteria containing plasmids,
were grown at 37 C in 2YT medium (Difco) supplemented with
chloramphenicol (30 lg/mL) and kanamycin (70 lg/mL). When
an OD600 of 1.5, was reached, protein production was induced with
1 mM isopropyl-b-D-1-thiogalactopyranoside (IPTG), and the cell
were to grow for an additional 3 h at 37 C. The cells were then pel-
leted by centrifugation and served as a protein puriﬁcation source.
The extracts were heated at 63 C for 10 min, and the denatured
proteins were removed by centrifugation. Because the isoelectric
points of all the proteins ranged from 4.35 to 4.91, the same proto-
col was used to purify all of them. Centrins 1, 2, and their variants
(full-length and C-terminal domains) were puriﬁed using three
successive chromatographic steps including DEAE-TSK (ion
exchange), phenyl-TSK (reversed phase) and G25 (gel ﬁltration).
Centrins were then lyophilized, and the degree of purity was
assessed using SDS–PAGE. Centrin concentration was determined
using UV absorption spectrophotometry at 280 nm using the
standard molar absorption coefﬁcient (EM) of 1490 M-1cm-1(1 residue tyrosine) for the full-length centrin or at 258 nm using
the standard molar absorption coefﬁcient (EM) of 1000 M-1cm-1
(5 residues phenylalanine) for the C-terminal domains.
4.4. In vitro phosphorylation of human centrins 1 and 2 by CK2
Samples of 250 lM centrin (wild type or variants) were phos-
phorylated using 1000 units of CK2 (Casein kinase II is composed
of two 44 kDa catalytic a-subunits and two 26 kDa regulatory b-
subunits; speciﬁc activity 859,000 units per mg) in 1 mL of Buffer
(50 mM Tris–HCl pH 7.5, 2 mM ATP, 10 mM MgCl2, 100 mM NaCl,
0.02% NaN3) in the absence or presence of 2 mM CaCl2 and 1 mM
EGTA. The incubation was carried out at 37 C for 40 h. Aliquots
(33 lL) were removed from the sample and immediately placed
in nitrogen liquid to stop the phosphorylation reaction. The ali-
quots were kept at20 C until HPLC analysis. A 10 lL aliquot from
the kinetic sample was added to 90 lL water and analyzed on a
DEAE-TSK 5PW column using HPLC. Phosphorylated and unphos-
phorylated centrins were separated using a linear gradient of 35–
65% buffer B (40 mM NaH2PO4 – 0.4 M NaCl, pH 7.86) completed
with buffer A (40 mM NaH2PO4 pH 7.86). Proteins and phosphory-
lated proteins were detected at 210 nm and 280 nm. The ratio of
phosphorylated and to non-phosphorylated proteins was deter-
mined by the integration of peaks using the program System Gold
(version 1990). The determination of phosphorylated residues was
assessed using MALDI-TOF mass spectrometry on tryptic frag-
ments of both C-HsCentrins 1 and 2.
All proteins (wild type and variants) were ﬁrst tested for their
stability in buffer (50 mM Tris–HCl pH 7.5, 10 mM MgCl2,
100 mM NaCl, 0.02% NaN3) at 37 C for 40 h, in the presence or
absence of 2 mM CaCl2.
4.5. Isothermal titration calorimetry (ITC)
The thermodynamic parameters of the molecular interactions
between human centrins (full-length 1 and 2 and their C-terminal
domains) and the target peptide were investigated via ITC using a
MicroCal MCS instrument (MicroCal Inc., Northampton, MA). The
protein and peptide were equilibrated in the same buffer (50 mM
MOPS, 100 mM NaCl pH 7.5) supplemented with 1 mM CaCl2 or
2 mM EDTA. The centrins (10 lM) in the calorimeter cell were
titrated with the peptide-target (100 lM) by automatic injections
of 8–10 lL at 30 C. On some occasions, the centrin/peptide target
ratio was 10–170 lM. The ﬁrst injection of 2 lL was ignored in the
ﬁnal data analysis. Integration of the peaks corresponding to each
injection and correction for the baseline were performed using the
Origin-based software provided by the manufacturer. The data
were ﬁtted to an interaction model to generate the stoichiometry
(n), equilibrium binding constant (Ka), and enthalpy of complex
formation (DH). Control experiments consisting of injections of
the peptide solution into the buffer were performed to evaluate
the heat of dilution.
4.6. Bioinformatics
Calculations of pI and PM were made using Expasy resources.
Multiple sequences alignments were performed using the Clu-
stalW program.
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